MedTrace Logo

Effect of Interleukin 6 Receptor Antagonists in SARS-CoV-2 Patients

NCT05367882 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2023-07-25

No results posted yet for this study

Summary

1. Investigate the possible effects of interleukin-6 receptor antagonists such as tocilizumab and sarilumab on the levels of IL-6, inflammtory and anti-inflammtory markers and cytokines before and after treatment in critically ill corona virus disease-19 patients.
2. Correlate between IL-6 levels with other inflammatory markers as ferritin and C-reactive protein.
3. investigate the possible changes on the levels of other inflammatory, anti-inflammatory markers and cytokines such as IL-10 and IP-10, before and after treatment.

Conditions

  • Corona Virus Infection

Interventions

DIAGNOSTIC_TEST

ELISA

collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • mohammad gamal abalrahman, lecturer · Assiut university, Egypt

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-07-20
Completion
2023-07-24

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05367882 on ClinicalTrials.gov